Major Drugmaker Loses $27 Billion After Heart Disease Drug Fails Phase III Trial

Two pharmaceutical companies announced that their jointly developed heart disease drug failed its Phase III trial, leading to a significant loss of $27 billion in market value for a major drugmaker.